Moxifloxacin-resistant and moxifloxacin-susceptible Staphylococcus aureus Keratitis: Outcomes from a 10-year retrospective study
Abstract
PURPOSE: Fluoroquinolones, specifically moxifloxacin are commonly used to treat bacterial keratitis. However, recent clinical evidence assessing the clinical outcomes in bacterial keratitis cases resistant to moxifloxacin remains sparse. This study evaluates the clinical characteristics and outcomes in cases of Staphylococcus aureus keratitis with in vitro resistance to moxifloxacin.
DESIGN: Retrospective clinical cohort study.
METHODS: Keratitis patients with cultures positive for Staphylococcus aureus at the University of Pittsburgh Medical Center, were identified between July 2012 and June 2022.
RESULTS: A total of 104 patients with culture-confirmed Staphylococcus aureus keratitis were included in the study. Patients infected by moxifloxacin-resistant bacteria (n = 32) were significantly older (74.32 ± 17.41 years) than moxifloxacin-susceptible infections (55.56 ± 20.86 years, p < 0.0001). Moxifloxacin resistance was identified in 29.8 % of cases, including methicillin-susceptible (4.8 %) and methicillin-resistant Staphylococcus aureus (25.96 %) isolates. The most common risk factors for moxifloxacin resistance were ocular surface disease (35.5 %) and history of prior infection (32.2 %). Moxifloxacin-resistant Staphylococcus aureus was associated with larger epithelial defects (18.18 ± 4.93 mm2 vs. 5.10 ± 0.76 mm2, p < 0.0001), longer healing times (42.42 ± 6.75 days vs. 32.2 ± 3.56 days, p < 0.0001), and higher rates of corneal perforation (19.3 % vs. 4.2 %; p =…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 104 participants or records.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.